Funding profile · Patient navigation software

Medumo

One Form D, $1,966,044 sold, 36 investors, and a trade sale to Royal Philips eighteen months later on terms nobody disclosed. The capital picture is small and the exit is real.

$1.97MEquity sold, the only Form D on record (Jan 2018)
$2.18MOffered in that round; $217,632 never sold
36Investors, all accredited, about $54,600 each
UndisclosedAcquisition price, Royal Philips, July 2019

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2013 Incorporated in Delaware Not disclosed Founders Form D
Before 2018 Y Combinator Not disclosed Y Combinator CNBC
2017 to 2018 PULSE@MassChallenge, two cohorts Not disclosed Accelerator, non-dilutive Accelerator
Dec 2017 to Jan 2018 Seed equity, Rule 506(b) $2,183,676 offered; $1,966,044 sold 36 accredited investors, none named Form D
2019, as reported Total raised $2.1M Not named Press reports
Pilot funding Brigham Care Redesign Incubator Startup Program Not disclosed Brigham and Women’s Hospital Partner
Jul 2019 Acquisition by Royal Philips Not disclosed Royal Philips (NYSE: PHG) Acquirer release

What the filings show

Medumo, Inc. · Form D · filed Jan 12, 2018

First sale
Dec 29, 2017
Offered
$2,183,676 equity
Sold
$1,966,044 · $217,632 remaining
Investors
36 · average about $54,612 · no non-accredited investors
Exemption
Rule 506(b)
Fees
Sales commissions $0 · finders fees $0 · minimum investment accepted $0
Related persons
Adeel Yang (executive officer, director); Jacob Cohen (executive officer); Satish Tadikonda (director); Laura Lang (director)
Issuer
Delaware corporation, incorporated 2013 · 401 Park Drive, Suite 207, Boston, MA
Filing
SEC EDGAR, CIK 0001727981, accession 0001727981-18-000001

Reading the filings

  1. One filing covers the entire disclosed history.Medumo registered with EDGAR in January 2018, five years after incorporation, and filed nothing further before the July 2019 sale. Companies raising under Section 4(a)(2) rather than Regulation D file no Form D at all, so earlier money may well have moved without leaving this trail.
  2. The checks were angel size, not fund size.$1,966,044 across 36 investors averages about $54,612 each. That is a syndicate of individuals and small vehicles, not a priced round led by an institution. No sales commission and no finders fee were reported, so no placement agent was compensated.
  3. The widely reported $2.1 million is the offering, not the closing.Fierce Healthcare, HIT Consultant and Observer all reported $2.1 million raised. The filing shows $2,183,676 offered and $1,966,044 taken in, leaving $217,632 unsold. MedCity News, which wrote “around $2 million,” is the closer figure.
  4. Two outside directors on a seed-stage board.The filing names Satish Tadikonda and Laura Lang as directors alongside Yang. For a company that had disclosed under $2 million, that is a more built-out board than the raise alone would predict.
  5. The exit price is not recoverable from public records.Philips did not disclose terms, Medumo did not, and no independent outlet obtained a figure. Philips reported 2018 sales of EUR 18.1 billion, so a transaction of this scale would not be separately disclosed in its accounts.
  6. Capital efficiency is the headline number here.On roughly $2 million of disclosed equity, the company reached more than 25 hospitals on its own count, four peer reviewed studies at three academic centers, and a strategic acquirer. Whether that produced a good return depends entirely on the undisclosed price.

Commercial signals

Signal Detail Source type
Named customers Brigham and Women’s Hospital, Massachusetts General Hospital, Partners HealthCare, Boston Children’s Hospital, UCSF, UPMC, University of Chicago Medicine. Independent and partner
Clinical evidence Four peer reviewed studies, 2019 to 2021, including a 121-patient randomized trial at Mount Sinai that names MEDUMO software. Peer reviewed
Regulatory No FDA 510(k) or PMA, no registered clinical trial, no NIH or NSF award found. Not found
Scale at exit Fewer than 30 employees. More than five million patient interactions claimed as of Jan 2019. Company-stated
After the sale Renamed Philips Patient Management; deployed at Boston Medical Center, Yale New Haven Health and Lahey Hospital and Medical Center during 2020. Acquirer-stated
Current status As of Sep 23, 2026 medumo.com does not resolve and the Philips landing page that carried the brand serves generic monitoring content. No retirement notice found. Checked

What to watch

  • Any Philips disclosure of the purchase price. None has appeared in seven years, and none is required.
  • Whether Philips still sells the product under any name, and under which business unit.
  • Comparable pricing in the category. Luma Health raised a $130 million Series C in November 2021 at far greater scale, which sets the ceiling this asset was never tested against.
  • Whether any Medumo investor has ever published a return on the position. None was found.

The Medumo story on Healthcare DiscoveryHealthcare Discovery

Related companies

Sources

  1. Public recordForm D, Medumo, Inc., CIK 0001727981SEC EDGAR · Jan 12, 2018
  2. Public recordPhilips expands patient management with the acquisition of MedumoRoyal Philips · Jul 18, 2019
  3. Peer reviewedFour studies in J Clin Gastroenterol, Telemedicine and e-Health, Int Forum Allergy Rhinol and Gastroenterology Nursing2019 to 2021
  4. IndependentPhilips acquires Boston start-up MedumoCNBC, Christina Farr · Jul 17, 2019
  5. IndependentPhilips acquires Boston-based patient navigation startup MedumoFierce Healthcare · Jul 18, 2019
  6. IndependentPhilips acquires Boston patient management startup MedumoMedCity News · Jul 21, 2019
  7. IndependentPhilips Acquires Patient Navigation Platform MedumoHIT Consultant · Jul 17, 2019
  8. IndependentLuma Health picks up $130MFierce Healthcare · Nov 23, 2021
  9. AcquirerPhilips Patient Management Solution during COVID-19Royal Philips · Nov 29, 2020
  10. CompanyBoston Children’s Hospital and Medumo strategic collaborationBusiness Wire · Jan 16, 2019

Compiled from SEC and other public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Medumo. This page is not an offer to sell or a recommendation to buy any security.